- AI
- Molecular Imaging
- CT
- X-Ray
- Ultrasound
- MRI
- Facility Management
- Mammography
FDA Clears New 1.5T MRI Coil
InkSpace Imaging’s 24-channel MRI coil, which will be included in Magnetom 1.5T scanners from Siemens Healthineers, reportedly facilitates quicker set-ups for technologists and enhanced spatial resolution.
The Food and Drug Administration (FDA) has granted 510(k) clearance for a 1.5T, 24-channel magnetic resonance imaging (MRI) coil, which reportedly enables improvements in workflow efficiency, image quality and patient comfort.
InkSpace Imaging, the developer of the new MRI coil, said high-density coil elements enhance spatial resolution and parallel imaging compatibility helps reduce artifacts while facilitating scan time reductions.
In addition to streamlining scan set-ups for technologists, the newly FDA-cleared 1.5T, 24-channel MRI coil bolsters spatial resolution and helps reduce artifacts, according to InkSpace Imaging, the developer of the new MRI coil. (Photo courtesy of InkSpace Imaging.)
The 1.5T MRI coil, which will be included in Magnetom MRI scanners from Siemens Healthineers, also streamlines scan set-ups for technologists, according to InkSpace Imaging. The company added that the ultra-lightweight coil conforms to patient anatomy, ensuring comfort for diverse body types.
“The 1.5T MR coil sets a new benchmark for image quality and operational efficiency, empowering radiologists to achieve better patient outcomes,” added Peter Fischer, the CEO of InkSpace Imaging.
Can MRI-Based AI Enhance Risk Stratification in Prostate Cancer?
January 13th 2025Employing baseline MRI and clinical data, an emerging deep learning model was 32 percent more likely to predict the progression of low-risk prostate cancer (PCa) to clinically significant prostate cancer (csPCa), according to new research.
Can MRI Have an Impact with Fertility-Sparing Treatments for Endometrial and Cervical Cancers?
January 9th 2025In a literature review that includes insights from recently issued guidelines from multiple European medical societies, researchers discuss the role of magnetic resonance imaging (MRI) in facilitating appropriate patient selection for fertility-sparing treatments to address early-stage endometrial and cervical cancer.
